Atossa Therapeutics, Inc.
ATOS
$0.83
-$0.08-8.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.92% | 2.78% | -1.14% | -3.84% | -5.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.42% | -1.90% | -10.25% | -11.97% | -3.31% |
| Operating Income | -11.42% | 1.90% | 10.25% | 11.97% | 3.31% |
| Income Before Tax | -12.15% | -10.84% | 11.27% | 15.25% | 9.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.15% | -10.84% | 11.27% | 15.25% | 9.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.15% | -10.84% | 11.27% | 15.25% | 9.79% |
| EBIT | -11.42% | 1.90% | 10.25% | 11.97% | 3.31% |
| EBITDA | -11.47% | 1.87% | 10.23% | 11.96% | 3.36% |
| EPS Basic | -9.42% | -8.91% | 11.95% | 15.09% | 9.11% |
| Normalized Basic EPS | -16.89% | -2.33% | 8.59% | 12.13% | 5.43% |
| EPS Diluted | -9.42% | -8.91% | 11.95% | 15.09% | 9.11% |
| Normalized Diluted EPS | -16.89% | -2.33% | 8.59% | 12.13% | 5.43% |
| Average Basic Shares Outstanding | 2.39% | 1.71% | 0.85% | -0.18% | -0.70% |
| Average Diluted Shares Outstanding | 2.39% | 1.71% | 0.85% | -0.18% | -0.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |